Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
RPRXRepros Therapeutics Inc. | -3.38% | - |
QTXBQuantRx Biomedical Corp. | +20.00% | - |
ATOSAtossa Genetics Inc. | +2.82% | - |
CTSOCytosorbents Corp. | -0.93% | - |
Great Basin Scientific, Inc. is a molecular diagnostic testing company, which focused on the development and commercialization of its patented, molecular diagnostic platform designed to test for infectious disease, especially hospital-acquired infections. Great Basin...
| Q2 2016 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Q3 2016 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Mar 2016 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | +52.72% | | ||||||||||
| Sales or Revenue | 731,422 | | ||||||||||
| Sales or Revenue Growth | +59.44% | | ||||||||||
| EBITDA | - | | ||||||||||
| 2015 | 5-year trend | |||||||||||
| Net Income Growth | -166.47% | | ||||||||||
| Sales or Revenue | 2.14 M | | ||||||||||
| Sales or Revenue Growth | +33.36% | | ||||||||||
| EBITDA | -20.79 M | |